Agendia and Ferrer in sales agreement for cancer diagnostic services
in European markets
17 September 2008
Agendia BV and Ferrer inCode have announced an agreement that will
give Ferrer exclusive rights to sell two of Agendia's signature cancer
diagnostic services — MammaPrint, a prognostic test that uses a 70-gene
signature to indicate risk of breast cancer tumor recurrence, and
CupPrint*, a gene expression profiling service which offers a fast and
reliable method of identifying the primary tumour site in Cancer of
Unknown Primary (CUP).
Under the exclusive distribution agreement, Ferrer has gained rights
to sell the tests in Germany, France, Italy, and Portugal, in addition
to a current agreement signed in 2007 covering Spain.
"We are confident that Ferrer inCode is the right partner for the
successful expansion of MammaPrint and CupPrint into these additional
European markets," said Dr. Bernhard Sixt, president and chief executive
officer of Agendia. "This agreement will allow us to increase the
availability of our services to more customers in these countries, with
the result being that more patients and their physicians will have
access to the valuable information provided by these tests."
MammaPrint is a clinically proven, highly accurate gene expression
profiling test that offers healthcare professionals a unique
personalized prognostic analysis to determine a patient's individual
risk of recurrence of breast cancer.
MammaPrint, the first In Vitro Diagnostic Multivariate Index Assay (IVDMIA)
to acquire market clearance from the US Food and Drug Administration
(February 2007) provides information that helps physicians and patients
to make more effective treatment decisions, which may include minimizing
the use of chemotherapy, thereby avoiding serious potential
side-effects. CupPrint is an innovative diagnostic service that
identifies the origin of the primary tumour in Cancer of Unknown
Primary, which accounts for up to five percent of all new cancer
referrals and is the fourth most common cause of cancer mortality
"Having followed the development of MammaPrint and CupPrint, we are
excited about the opportunity for Ferrer inCode to expand the
commercialization of these gene expression profiling tools in these four
European countries," said Dr. Carlos de Lecea, vice president,
International and Business Development at Ferrer. "Both tests provide
valuable information that can be used to guide the therapeutic decision
making process of oncologists, opening the door to a more personalized
treatment for cancer patients."
The companies say they are also discussing the possibility of future
cooperation and expansion into other parts of the world.